fournierplayingcards| Average weight loss in 24 weeks was 18.8%; Roche announced positive results for Phase 1 of a new GLP-1/GIP drug

News summary

Roche announced that its GLP-1/GIP dual receptor agonist CT-388 has been used in obese people.fournierplayingcardsThe Phase 1 trial achieved positive results. Compared to placebo, healthy obese adults, once a week subcutaneous injection of CT-388 for 24 weeks, significantly lost weight, with the placebo-adjusted average weight loss rate offournierplayingcards.fournierplayingcards..

Newsletter text

Roche announced that its Phase 1 trial of GLP-1/GIP dual receptor agonist CT-388 has achieved positive results in obese people. Compared with placebo, CT-388 administered subcutaneously once a week for 24 weeks in healthy obese adults significantly lost weight. The placebo-adjusted average weight loss rate was 18.8%(p-value\u003c0.001), achieving statistical and clinical significance.

（fournierplayingcards: Congratulations